Jonathan W Goldman

Plain English
This study looked at a combination treatment of osimertinib and savolitinib for patients with a specific type of lung cancer (EGFR-mutated advanced NSCLC) who didn't respond to initial osimertinib therapy. Among the 32 patients treated, 47% saw their tumors shrink, and the treatment provided a median overall survival of about 20.7 months. This is important because it offers a potential new treatment option for patients facing resistance after first-line therapy. Who this helps: This helps patients with advanced lung cancer who have specific genetic changes that make their disease harder to treat.

Plain English
This research paper looks at the latest recommendations for diagnosing and treating small cell lung cancer. It highlights key updates, especially in the use of systemic therapies and radiation, to improve patient outcomes. These updates are important because they help ensure that patients receive the most effective and current treatments available. Who this helps: Patients with small cell lung cancer and their doctors.

Plain English
This study examined a new treatment combining osimertinib and datopotamab deruxtecan for patients with advanced non-small-cell lung cancer who had previously progressed on osimertinib alone. Out of 69 patients, the treatment showed a confirmed objective response rate of 43% for those receiving a lower dose (4 mg/kg) and 36% for a higher dose (6 mg/kg). It also achieved a median overall survival of 19.8 months for the lower dose and 26.2 months for the higher dose, indicating the combination can be beneficial despite some patients experiencing severe side effects. Who this helps: This helps patients with EGFR-mutated advanced lung cancer who need new treatment options after their initial therapy has failed.

Plain English
This study looked at patients with non-small cell lung cancer who have a mutation in the epidermal growth factor receptor (EGFR) and had their cancer progress after starting treatment with osimertinib. Researchers found that 87% of tumor and blood samples showed changes in the tumor's genes that could explain why the treatment stopped working, while 85% had specific genetic alterations in TP53 and MDM2/4. These findings are important because they can guide doctors in choosing better second-line treatments for patients, improving their chances of successful outcomes. Who this helps: This helps patients with non-small cell lung cancer and their doctors by providing insights for future treatments.

Plain English
Researchers studied a drug called ziftomenib, designed to block the interaction between two proteins, menin and KMT2A, which are involved in certain types of acute leukemia. They found that ziftomenib effectively slowed the growth of leukemia cells and reduced cancer in lab models, achieving a significant reduction in key cancer-related genes. Notably, it was still effective against some resistant leukemia mutations, with a potency of less than 25 nanomolar in certain cases. Who this helps: This helps adult patients with specific types of acute leukemia, particularly those with NPM1 mutations or KMT2A rearrangements.

Plain English
This study looked at a new treatment called setidegrasib for patients with advanced non-small-cell lung cancer (NSCLC) and pancreatic cancer that have a specific genetic variant known as p.G12D. Out of 76 patients with NSCLC treated with a dose of 600 mg, 36% showed signs of improvement, with an average of about 8.3 months without the disease worsening, while in pancreatic cancer patients, 24% showed a response, with an average survival of 10.3 months. These findings indicate that setidegrasib may effectively treat patients with these difficult-to-treat cancers and has manageable side effects. Who this helps: Patients with advanced non-small-cell lung cancer and pancreatic cancer who have the p.G12D variant.

Plain English
This study looked at a 68-year-old man with stage III lung cancer who developed severe lung and liver problems after receiving immunotherapy and chemotherapy. He was successfully treated with a double lung and liver transplant, and one year later, he showed no signs of cancer returning. This is important because it shows that in certain patients, organ transplants can save lives even after aggressive cancer treatments have caused serious organ damage. Who this helps: This helps cancer patients experiencing severe organ damage from treatment, as well as their doctors.

Plain English
This study looked at how well a drug called neratinib works for patients with a specific type of lung cancer that has a rare mutation in the EGFR gene. Out of 31 patients treated, 19.4% had a positive response to the drug at 8 weeks, and the average time before their cancer progressed was about 5.75 months. This matters because there are very few treatment options available for patients with this mutation after previous therapies have failed, so finding effective solutions is crucial. Who this helps: This helps patients with EGFR exon 18-mutant non-small-cell lung cancer.

Plain English
This study looked at how well a drug called osimertinib helps patients with a certain type of lung cancer after surgery. They found that 86% of patients taking osimertinib were free of disease or waiting to have another treatment after three years, compared to only 36% in the placebo group. This matters because it suggests that monitoring specific markers in the blood (called molecular residual disease or MRD) could help predict if and when cancer might come back, potentially leading to longer and more effective treatment plans. Who this helps: Patients with resected EGFR-mutated non-small-cell lung cancer.

Plain English
This study focused on a new drug, PF-06873600, designed to help patients with advanced breast cancer, including those with triple-negative breast cancer and ovarian cancer. Researchers gave the drug to 78 patients, found that the best dose was 25 mg taken twice daily, and observed some cancer shrinkage: 6.7% of patients in one group and 22.7% in another showed partial responses. This matters because it provides hope for a new treatment option that specifically targets breast cancers resistant to typical therapies. Who this helps: This helps patients with hormone receptor-positive breast cancer and their doctors.

Plain English
This study looked at the side effects experienced by patients with advanced small-cell lung cancer who were treated with a combination of durvalumab and standard chemotherapy, platinum-etoposide. Out of 537 patients, only a small percentage reported side effects, with 34-41% mentioning dry mouth and 3-5% experiencing hand-foot syndrome before treatment. Understanding these patient-reported side effects is important as it offers a clearer picture of how the treatment affects daily life, which can help improve care strategies. Who this helps: This helps patients and doctors by providing better insights into treatment side effects.

Plain English
This study focused on small cell lung cancer (SCLC) in patients who have never smoked, comparing their tumors to those of patients with a history of smoking. The researchers found that SCLC in never-smokers had less than half the rate of certain mutations, like TP53 (59% compared to 85%), and a higher rate for others, like EGFR mutations (26% compared to 2.6%). These differences are important because they suggest that lung cancer in never-smokers may develop through different genetic pathways than in smokers, which could influence treatment options. Who this helps: This helps patients who never smoked and their doctors in understanding lung cancer better and tailoring treatments specifically for them.

Plain English
Researchers studied the effectiveness of amivantamab, a new treatment, in patients with advanced lung cancer who have specific genetic mutations known as MET exon 14 skipping mutations. Out of 97 patients, 32% had a positive response to the treatment overall, with a higher response of 50% in those who had not been treated before. This treatment is important because it shows promise for patients who have not responded to other therapies, with an average overall survival of 15.8 months. Who this helps: This benefits patients with advanced NSCLC and MET exon 14 skipping mutations.

Plain English
This study looked at the effectiveness and safety of combining two drugs, osimertinib and necitumumab, in patients with a specific type of advanced lung cancer that had worsened after initial treatment. Out of 19 patients, only 11% saw any significant improvement, and those who did had their cancer respond for about 10 to 6 months. The average survival for all patients was about 11.4 months, but there were also serious side effects reported in over half of the patients, such as blood clots. Who this helps: This research helps doctors understand treatment options for patients with resistant lung cancer.

Plain English
This study looked at the combination of two drugs, encorafenib and binimetinib, in patients with a specific type of lung cancer known as BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC). Results showed that 75% of patients who had not received treatment before experienced a positive response to the drugs, with an average response lasting over 40 months, while 46% of patients who had already been treated before had a response lasting about 16.7 months. The findings highlight that this drug combination can effectively fight this type of cancer, especially for patients starting treatment for the first time, although some patients experienced side effects like nausea and fatigue. Who this helps: This helps patients with BRAF V600E-mutant metastatic NSCLC.

Plain English
Researchers studied a new drug called TNG260 designed to help patients with non-small cell lung cancer (NSCLC) whose tumors carry a mutation in the STK11 gene, which makes them resistant to existing immunotherapies like anti-PD-1. They found that TNG260 enhanced the effectiveness of anti-PD-1 treatment by increasing immune activity in tumors, leading to better outcomes in animal models and increased immune response in patients from a clinical trial. This matters because it offers a new approach to help patients who currently have limited treatment options due to their specific cancer genetics. Who this helps: Patients with STK11-mutant non-small cell lung cancer.

Plain English
This study looked at a new treatment for extensive-stage small-cell lung cancer (ES-SCLC), combining a drug called durvalumab with chemotherapy (etoposide and either carboplatin or cisplatin). It found that patients who received this combination lived longer, with a survival benefit of 29% for those younger than 70 and 24% for men compared to those who only received chemotherapy. The results are important because they show that the combination treatment is better than chemotherapy alone and can be a standard option for these patients. Who this helps: This benefits patients with extensive-stage small-cell lung cancer, especially those starting treatment.

Plain English
This study looked at the effectiveness of a drug called poziotinib in patients with a specific type of lung cancer that has a genetic change known as EGFR exon 20 insertion. Although only 14.8% of all patients responded well to the drug overall, those with near-loop insertions had a significant benefit, showing a 25.9% reduction in tumor size and an average survival without disease progression of 11.1 months, compared to just 3.5 months for far-loop insertions. This research is important because it demonstrates that the location of the genetic change can affect how well patients respond to certain cancer treatments, which could lead to more tailored therapies for patients. Who this helps: Patients with EGFR exon 20 insertion lung cancer, particularly those with near-loop insertions.

Plain English
This study examined the effectiveness of two medications, encorafenib and binimetinib, in patients with a specific type of advanced lung cancer that has a BRAF V600E mutation. In treatment-naïve patients, the average survival time was about 47.6 months, and nearly 49% were still alive after four years. For those who had previously received treatment, the average survival was 22.7 months with about 31% surviving for four years. Who this helps: This benefits patients with BRAF V600E-mutant metastatic non-small cell lung cancer.

Plain English
In this study, researchers looked at how well a new treatment combining durvalumab and platinum-etoposide worked compared to platinum-etoposide alone in patients with extensive-stage small cell lung cancer. They found that the combination treatment significantly improved survival rates, with a hazard ratio indicating a 53% lower risk of death compared to the standard treatment. This is important because it shows that adding durvalumab can benefit a majority of patients, regardless of specific genetic markers like PD-L1 expression. Who this helps: This helps patients with extensive-stage small cell lung cancer.

Plain English
This study looked at a treatment approach for patients with locally advanced, inoperable non-small cell lung cancer (NSCLC) by using a combination of chemotherapy and a special type of radiation therapy called stereotactic ablative radiotherapy (SABR). Researchers found that patients who received higher doses of SABR had a 100% rate of local control of the cancer after two years, and those in the high-dose group had a 55.6% overall survival rate, compared to only 30% in the low-dose group. These results show that this treatment strategy is not only safe but also improves outcomes for these patients significantly. Who this helps: This helps patients with advanced lung cancer who cannot have surgery.

Plain English
The PHAROS study examined a combination of two drugs, encorafenib and binimetinib, for treating patients with a specific type of advanced lung cancer that carries a BRAF V600E mutation. Among the 59 patients who had not received prior treatment, 75% saw their tumors shrink or disappear, while 46% of those who had been treated before experienced similar results. This significant response rate points to a promising new treatment option for patients with this type of lung cancer. Who this helps: This benefits patients with metastatic non-small-cell lung cancer who have the BRAF V600E mutation.

Plain English
This study looked at how sleep problems affect the mental and physical health of people with lung cancer, especially in relation to the stigma and discrimination they face. It found that higher levels of discrimination led to more sleep issues, which in turn increased feelings of distress and worsened physical symptoms. For instance, every unit increase in discrimination linked to a 5.52-point rise in sleep disruption. Who this helps: This research benefits lung cancer patients by highlighting the impact of stigma on their overall well-being.

Plain English
The research studied the impact of a drug called osimertinib on patients with early-stage non-small cell lung cancer (NSCLC) that has specific genetic mutations. It found that patients taking osimertinib had a 51% lower risk of dying compared to those who received a placebo, showing that osimertinib significantly improves overall survival after surgery. This is important because it offers a promising treatment option for patients with this type of lung cancer to live longer and healthier lives. Who this helps: This helps patients with EGFR-mutated non-small cell lung cancer.

Plain English
This study looked at how families of children with cancer remember and respond to genetic findings from advanced testing that identifies harmful genetic variants related to cancer. Out of 740 pediatric oncology patients, 96 had such variants, and among those contacted for the survey, 69.8% were able to correctly recall their genetic findings. The study revealed that 47.2% of families adjusted their child's cancer treatment based on the results, and most (83.0%) shared the findings with family members, highlighting the importance of genetic information in treatment decisions. Who this helps: This helps patients and families dealing with pediatric cancer.

Plain English
This study looked at a new cancer vaccine combined with immune checkpoint inhibitors to see if it was safe and effective for patients with advanced solid tumors. In the trial, most patients had mutations in a gene called KRAS, and while the vaccine was generally well tolerated, it did not show a positive effect, with an overall response rate of 0%. The median time without cancer progression was about 1.9 months and the median overall survival was 7.9 months, prompting researchers to develop a new vaccine targeting only KRAS mutations. Who this helps: This helps cancer patients with KRAS mutations and their doctors.

Plain English
This study looked at how certain biological markers can predict how well patients with advanced small-cell lung cancer respond to immunotherapy drugs in a clinical trial involving over 800 patients. They found that patients with a specific tumor profile, particularly those with high levels of certain immune markers, lived longer when treated with a combination of drugs compared to those who only received standard chemotherapy; for instance, those with high CD4 expression had a median survival of 25.9 months compared to 11.4 months with standard treatment. These results highlight the importance of understanding the tumor environment in improving treatment outcomes for this aggressive cancer. Who this helps: This helps patients with extensive-stage small-cell lung cancer by identifying who might benefit the most from immunotherapy.

Plain English
This study looked at a new treatment combining two drugs, capmatinib and trametinib, for patients with a type of lung cancer that has specific genetic changes (like MET exon 14 skipping mutations) and who have not responded well to standard MET inhibitor therapy. Researchers enrolled up to 18 patients in the first phase of the trial and plan to expand the study to better understand the safety of this drug combination. The findings are important because they could provide an effective treatment option for patients whose cancer has stopped responding to existing therapies. Who this helps: This helps patients with nonsmall cell lung cancer who have specific MET alterations and have not found success with other treatments.

Plain English
This study looked at how combining two types of immune therapies—CTLA4 inhibitors and PD-L1 inhibitors—affects patients with advanced non-small-cell lung cancer (NSCLC), especially those with mutations in certain genes (STK11 and KEAP1). It found that patients with these mutations benefited significantly from the combination treatment, showing better anti-tumor responses compared to those who received PD-L1 inhibitors alone; specifically, the presence of KEAP1 mutations was identified as a strong predictor of treatment success. This matters because it helps identify which patients are more likely to benefit from a more aggressive treatment strategy, potentially improving outcomes for those with resistant cancer types. Who this helps: Patients with non-small-cell lung cancer who have STK11 or KEAP1 mutations.

Plain English
This study focused on the combination of two drugs, Telisotuzumab vedotin (Teliso-V) and erlotinib, to treat patients with a type of lung cancer called non-small-cell lung cancer (NSCLC) that overexpresses the c-Met protein. Out of 36 patients who were evaluated, the results showed that those with the most c-Met expression had a 52.6% response rate to the treatment, and the average time before the cancer worsened was about 6.8 months for patients without a specific mutation (T790M). These findings are significant because they indicate that this drug combination could be a promising option for patients who have limited treatment alternatives. Who this helps: Patients with c-Met-positive non-small-cell lung cancer.

Plain English
This study looked at a type of leukemia called B-cell acute lymphoblastic leukemia (B-ALL) that has genetic issues related to the ETV6 gene. Researchers found that when the ETV6 gene is not functioning properly, it causes specific regions of DNA (called GGAA repeats) to activate improperly, leading to the growth of cancerous cells. They determined that this faulty activation is linked to important genes driving the leukemia, which means targeting these mechanisms could help change the course of the disease. Who this helps: This research benefits patients with ETV6-deficient B-ALL and their doctors by guiding potential new treatment strategies.

Plain English
This study examined the effectiveness of the drug osimertinib in preventing cancer from returning in patients with early-stage lung cancer that has specific genetic mutations. Researchers found that after 3 years, 70% of patients taking osimertinib were free from disease recurrence, compared to just 29% for those receiving a placebo. This matters because it shows that osimertinib significantly improves the chances of staying cancer-free for patients with these mutations after surgery. Who this helps: This helps patients with EGFR-mutated non-small-cell lung cancer who have undergone surgery.

Plain English
This study looked at a combination treatment of nivolumab and ipilimumab for patients with advanced non-small cell lung cancer (NSCLC), including those who are in worse physical condition (ECOG performance status 2) and other special cases. The researchers found that while patients experienced some serious side effects, like pneumonia and diarrhea, the treatment was generally manageable, with a three-year survival rate of 33.7% for healthier patients and 20.5% for those in more challenging situations. This matters because it shows that even patients with additional health challenges may benefit from this treatment approach, helping improve their chances of survival. Who this helps: Patients with advanced NSCLC, especially those with poorer health or additional complications.

Plain English
This study looks at the cancer drug osimertinib in patients who have had surgery for a specific type of lung cancer called stage IA2-IA3 EGFR-mutated non-small cell lung cancer. Researchers are comparing osimertinib to a placebo (an inactive pill) to see if it helps patients stay cancer-free longer after surgery. The main goal is to find out if the drug improves the time patients remain free of cancer, with results expected in 2027. Who this helps: This helps lung cancer patients who have undergone surgery and have EGFR mutations.

Plain English
This study looked at the effects of combining radiation therapy with a drug called osimertinib in patients with advanced lung cancer. Out of 16 patients, 56% developed moderate pneumonitis (inflammation of the lungs), while 37.5% had more severe cases that required steroids, and 6.3% had the most serious level of lung inflammation. This finding is important because it highlights the significant risk of severe lung problems when these two treatments are used together, which could impact how doctors choose to treat lung cancer patients. Who this helps: This information benefits doctors and patients with advanced lung cancer.

Plain English
This study looked at how well the drugs osimertinib and selpercatinib work together for patients with advanced lung cancer caused by specific genetic changes (EGFR mutations and RET fusions) who previously did not respond to osimertinib alone. Of 14 patients treated, 50% showed a positive response to the combination therapy, with an 83% rate of disease control for an average of about 8 months. This is important because it shows that combining these treatments can be beneficial for patients who have developed resistance to traditional therapies. Who this helps: Patients with advanced EGFR-mutant lung cancer who have developed resistance to treatment.

Plain English
This study investigated the effects of a drug called osimertinib on patients with early-stage lung cancer that has specific genetic mutations. After three years, patients taking osimertinib had a longer time without their cancer returning compared to those taking a placebo, with 35.8 months of treatment for osimertinib versus 25.1 months for placebo. The drug also showed good safety, with most side effects seen early and quality of life remaining stable over the treatment period, which reinforces its use for these patients. Who this helps: This benefits patients with EGFR-mutated non-small cell lung cancer.

Plain English
This study looked at the combination of two drugs, encorafenib and binimetinib, to treat patients with a specific type of lung cancer called BRAF-mutant metastatic non-small-cell lung cancer (NSCLC). The results showed that 75% of patients who had not received treatment before responded positively to the drugs, while 46% of those who had received treatment before had similar outcomes. This matters because it indicates that this drug combination could be an effective treatment option for patients with this type of lung cancer. Who this helps: Patients with BRAF-mutant metastatic non-small-cell lung cancer.

Plain English
Researchers studied the impact of a drug called osimertinib on patients with early-stage non-small-cell lung cancer (NSCLC) that had a specific genetic mutation. They found that patients taking osimertinib had a 5-year overall survival rate of 88%, compared to 78% for those receiving a placebo. This means that the drug significantly improves the chances of surviving for five years after treatment. Who this helps: This helps lung cancer patients with specific mutations, as well as their doctors managing their treatment.

Plain English
This study focused on a patient with early-stage non-small cell lung cancer that has a specific genetic mutation. The patient took a drug called selpercatinib for 8 weeks before surgery, and doctors found that there was no viable tumor remaining after treatment. This is important because it shows that selpercatinib could potentially be effective in treating early-stage cancer and may improve outcomes for patients with this type of lung cancer. Who this helps: This helps patients with fusion-positive non-small cell lung cancer.

Plain English
This research focused on a treatment combination of drugs—neratinib, fulvestrant, and trastuzumab—for patients with a type of advanced breast cancer that has a specific HER2 mutation. The study involved 71 patients, revealing that those receiving the full combination had a response rate of 39% and could live without disease progression for an average of 8.3 months. These findings are significant because they help identify effective treatment options for patients who did not respond to prior therapies and have been included in important cancer treatment guidelines. Who this helps: This benefits patients with advanced, hormone receptor-positive, HER2-mutant breast cancer.

Plain English
In this study, researchers looked at a new treatment involving a drug called amivantamab combined with chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (exon 20 insertions). They found that patients who received the combination treatment had a median progression-free survival of 11.4 months, compared to just 6.7 months for those on chemotherapy alone, and significantly more patients saw their cancer shrink—73% versus 47%. This matters because it shows that adding amivantamab can greatly improve outcomes for a difficult-to-treat group of cancer patients. Who this helps: This helps patients with advanced NSCLC who have exon 20 insertions.

Plain English
This study examined how effective a treatment combining emibetuzumab and erlotinib was for lung cancer patients who had developed resistance to erlotinib and had high levels of a protein called MET. Out of 111 patients, only a small percentage saw improvements: 3% with the combination treatment and 4.3% with just emibetuzumab. However, combining treatments did lead to better overall disease management, with a 50% control rate and an average time without disease progression of 3.3 months compared to 1.6 months for emibetuzumab alone. Who this helps: Patients with non-small cell lung cancer who have developed resistance to standard treatments.

Plain English
This study looked at the drug MEDI0562 combined with either durvalumab or tremelimumab to see if it was safe and tolerable for adults with advanced solid tumors that had already been treated. The researchers tested different doses on 58 patients, finding that 74% of those on the MEDI0562 and durvalumab combination and 68% on the MEDI0562 and tremelimumab combination experienced some side effects. Even though some patients showed positive signs, the overall effectiveness was not strong, and moderate side effects were common. Who this helps: This research helps patients with advanced solid tumors seeking new treatment options.

Plain English
The study examined how effective a treatment combining durvalumab with chemotherapy is for patients with extensive-stage small cell lung cancer, particularly focusing on those with brain metastases. It found that patients receiving the durvalumab treatment lived longer compared to those who only got chemotherapy, regardless of whether they had brain metastases. Specifically, the treatment improved overall survival by a factor of 0.79 for those with brain metastases and 0.76 for those without. Who this helps: Patients with extensive-stage small cell lung cancer, including those with brain metastases.

Plain English
This study looked at the drug selpercatinib to see if it helps patients with early-stage lung cancer that has specific genetic changes. The researchers found that patients who received selpercatinib had a better chance of staying cancer-free for a longer period compared to those who received a placebo; specifically, the study measured how long patients remained cancer-free (event-free survival). This is important because it means selpercatinib could be an effective treatment option for people with this type of lung cancer after surgery or radiation. Who this helps: This helps patients with fusion-positive non-small-cell lung cancer and their doctors.

Plain English
This study looked at the effects of combining chemotherapy with immune checkpoint inhibitors (ICIs) in patients with advanced lung cancer caused by specific mutations. Researchers evaluated 246 patients and found no significant difference in how long patients lived without their cancer getting worse (progression-free survival) or overall survival between those treated with chemotherapy plus ICIs and those treated with chemotherapy alone. The findings suggest that patients who already received certain targeted therapies (TKIs) may not benefit from adding ICIs to their chemotherapy. Who this helps: This information is beneficial for doctors treating patients with advanced lung cancer and helps guide treatment decisions for those with specific genetic mutations.